Compare AJANTA PHARMA with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA CIPLA AJANTA PHARMA/
CIPLA
 
P/E (TTM) x 24.7 29.1 84.7% View Chart
P/BV x 6.9 4.1 166.6% View Chart
Dividend Yield % 0.5 0.5 103.5%  

Financials

 AJANTA PHARMA   CIPLA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
CIPLA
Mar-20
AJANTA PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,422586 242.9%   
Low Rs898357 251.6%   
Sales per share (Unadj.) Rs233.5207.0 112.8%  
Earnings per share (Unadj.) Rs44.018.6 236.4%  
Cash flow per share (Unadj.) Rs52.233.2 157.3%  
Dividends per share (Unadj.) Rs9.004.00 225.0%  
Dividend yield (eoy) %0.80.8 91.4%  
Book value per share (Unadj.) Rs255.1195.5 130.5%  
Shares outstanding (eoy) m88.02806.35 10.9%   
Bonus/Rights/Conversions BBESOS-  
Price / Sales ratio x5.02.3 218.3%   
Avg P/E ratio x26.425.3 104.1%  
P/CF ratio (eoy) x22.214.2 156.5%  
Price / Book Value ratio x4.52.4 188.6%  
Dividend payout %20.521.5 95.2%   
Avg Mkt Cap Rs m102,081379,912 26.9%   
No. of employees `0006.825.8 26.3%   
Total wages/salary Rs m4,30730,270 14.2%   
Avg. sales/employee Rs Th3,022.66,459.6 46.8%   
Avg. wages/employee Rs Th633.41,171.2 54.1%   
Avg. net profit/employee Rs Th569.1580.2 98.1%   
INCOME DATA
Net Sales Rs m20,554166,949 12.3%  
Other income Rs m2113,442 6.1%   
Total revenues Rs m20,765170,391 12.2%   
Gross profit Rs m5,66432,060 17.7%  
Depreciation Rs m72111,747 6.1%   
Interest Rs m121,974 0.6%   
Profit before tax Rs m5,14321,782 23.6%   
Minority Interest Rs m0-475 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,2736,312 20.2%   
Profit after tax Rs m3,87014,995 25.8%  
Gross profit margin %27.619.2 143.5%  
Effective tax rate %24.829.0 85.4%   
Net profit margin %18.89.0 209.6%  
BALANCE SHEET DATA
Current assets Rs m11,812117,038 10.1%   
Current liabilities Rs m3,77643,931 8.6%   
Net working cap to sales %39.143.8 89.3%  
Current ratio x3.12.7 117.4%  
Inventory Days Days7796 80.8%  
Debtors Days Days8285 95.9%  
Net fixed assets Rs m14,398107,424 13.4%   
Share capital Rs m1751,613 10.9%   
"Free" reserves Rs m22,277156,018 14.3%   
Net worth Rs m22,452157,630 14.2%   
Long term debt Rs m723,693 0.0%   
Total assets Rs m26,962236,626 11.4%  
Interest coverage x444.312.0 3,691.5%   
Debt to equity ratio x00.2 0.2%  
Sales to assets ratio x0.80.7 108.0%   
Return on assets %14.47.2 200.7%  
Return on equity %17.29.5 181.2%  
Return on capital %23.012.8 178.7%  
Exports to sales %033.0 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,175 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,68256,036 19.1%   
Fx outflow Rs m2,1026,764 31.1%   
Net fx Rs m8,58049,272 17.4%   
CASH FLOW
From Operations Rs m3,74830,685 12.2%  
From Investments Rs m-2,2281,040 -214.1%  
From Financial Activity Rs m-1,475-29,488 5.0%  
Net Cashflow Rs m452,340 1.9%  

Share Holding

Indian Promoters % 73.8 16.0 461.3%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 1.6 12.2 12.7%  
FIIs % 7.6 23.7 32.1%  
ADR/GDR % 0.0 1.1 -  
Free float % 17.0 26.2 64.9%  
Shareholders   20,968 161,166 13.0%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  FDC  TORRENT PHARMA  STRIDES PHARMA SCIENCE  

Compare AJANTA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

A Time Correction in the Nifty(Momentum Moves)

The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Mar 5, 2021 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - SHASUN PHARMA COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS